(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) jumped by a staggering 10.77% to 0.91 € at 10:55 EST on Monday, following the last session’s upward trend. CAC 40 is rising 0.4% to 7,158.26 €, following the last session’s downward trend. This seems, as yet, a somewhat positive trend trading session today.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of -3.99 €.
Volume
Today’s last reported volume for ERYTECH PHARMA is 286584 which is 50.97% below its average volume of 584624.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, ERYTECH PHARMA’s stock is considered to be oversold (<=20).
Volatility
ERYTECH PHARMA’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.09%, a positive 4.25%, and a positive 5.38%.
ERYTECH PHARMA’s highest amplitude of average volatility was 3.86% (last week), 8.16% (last month), and 5.38% (last quarter).
More news about ERYTECH PHARMA (ERYP.PA).
